These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 14527406)

  • 1. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Stopak K; de Noronha C; Yonemoto W; Greene WC
    Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    Liu B; Yu X; Luo K; Yu Y; Yu XF
    J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
    Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
    J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Sheehy AM; Gaddis NC; Malim MH
    Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional domains of APOBEC3G required for antiviral activity.
    Li J; Potash MJ; Volsky DJ
    J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
    Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
    J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Marin M; Rose KM; Kozak SL; Kabat D
    Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Sheehy AM; Gaddis NC; Choi JD; Malim MH
    Nature; 2002 Aug; 418(6898):646-50. PubMed ID: 12167863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
    Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
    J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Yu X; Yu Y; Liu B; Luo K; Kong W; Mao P; Yu XF
    Science; 2003 Nov; 302(5647):1056-60. PubMed ID: 14564014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protecting APOBEC3G: a potential new target for HIV drug discovery.
    Stopak K; Greene WC
    Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study.
    Bernacchi S; Henriet S; Dumas P; Paillart JC; Marquet R
    J Biol Chem; 2007 Sep; 282(36):26361-8. PubMed ID: 17609216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Conticello SG; Harris RS; Neuberger MS
    Curr Biol; 2003 Nov; 13(22):2009-13. PubMed ID: 14614829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The viral infectivity factor (Vif) of HIV-1 unveiled.
    Rose KM; Marin M; Kozak SL; Kabat D
    Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
    Schröfelbauer B; Chen D; Landau NR
    Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3927-32. PubMed ID: 14978281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
    J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.